Zobrazeno 1 - 10
of 145
pro vyhledávání: '"Mallikarjuna, Rettiganti"'
Publikováno v:
The Journal of Headache and Pain, Vol 22, Iss 1, Pp 1-10 (2021)
Abstract Background Patients with episodic migraine (EM) with a higher-frequency of migraine headache days (HFEM: 8–14 migraine headache days/month) have a greater disease burden and a higher risk of progressing to chronic migraine (CM) with associ
Externí odkaz:
https://doaj.org/article/94ea66fe5df7429ba2ed4ac69b2a3823
Autor:
Michael Ament, Kathleen Day, Virginia L Stauffer, Vladimir Skljarevski, Mallikarjuna Rettiganti, Eric Pearlman, Sheena K. Aurora
Publikováno v:
The Journal of Headache and Pain, Vol 22, Iss 1, Pp 1-10 (2021)
Abstract Background Galcanezumab, a humanized monoclonal antibody that binds calcitonin gene-related peptide, has demonstrated a significant reduction in monthly migraine headache days compared with placebo. Here, we analyze data from 3 randomized cl
Externí odkaz:
https://doaj.org/article/7e0f3e29ff50462e83bb91f2aef26788
Publikováno v:
The Journal of Headache and Pain, Vol 21, Iss 1, Pp 1-9 (2020)
Abstract Background Focus on the frequency of migraine pain may undervalue the total burden of migraine as pain duration and severity may present unique, additive burden. A composite measure of total pain burden (TPB; frequency, severity, and duratio
Externí odkaz:
https://doaj.org/article/54ef347b35ed4aff8c8a0a3979dce2e0
Autor:
Brian Plato, J Scott Andrews, Mallikarjuna Rettiganti, Antje Tockhorn-Heidenreich, Jennifer Bardos, Richard Wenzel, Dulanji Kuruppu, Anna Ambrosini
Publikováno v:
Cephalalgia Reports, Vol 4 (2021)
Objective: The efficacy of galcanezumab was evaluated in patients with episodic cluster headache and history of preventive treatment failure. Methods: In the randomized, 8-week, double-blind study (CGAL), patients with episodic cluster headache recei
Externí odkaz:
https://doaj.org/article/027b8314f4c949e4a23113a3027be53c
Autor:
Michael Ament, Kathleen Day, Virginia L. Stauffer, Vladimir Skljarevski, Mallikarjuna Rettiganti, Eric Pearlman, Sheena K. Aurora
Publikováno v:
The Journal of Headache and Pain, Vol 22, Iss 1, Pp 1-2 (2021)
Externí odkaz:
https://doaj.org/article/5240f84726784d70ad35407c5199847a
Publikováno v:
Annals of Pediatric Cardiology, Vol 11, Iss 1, Pp 48-55 (2018)
Background : The existing training pathways to become a pediatric cardiac intensivist are very variable with physicians coming from varied training backgrounds of pediatric critical care, pediatric cardiology, neonatology, or pediatric anesthesia. Ai
Externí odkaz:
https://doaj.org/article/eda19773eb8e4606a808905f89638230
Autor:
Jessica, Ailani, Jeffrey Scott, Andrews, Antje, Tockhorn-Heidenreich, Richard, Wenzel, Mallikarjuna, Rettiganti
Publikováno v:
Advances in Therapy. 39:4544-4555
In evaluating therapies for migraine prevention, emphasis is placed on frequency and less attention is paid to duration or severity. Total pain burden (TPB) combines frequency, duration, and severity of migraine headache, and has the potential to fur
Publikováno v:
The Journal of Headache and Pain, Vol 22, Iss 1, Pp 1-10 (2021)
The Journal of Headache and Pain
The Journal of Headache and Pain
Background Patients with episodic migraine (EM) with a higher-frequency of migraine headache days (HFEM: 8–14 migraine headache days/month) have a greater disease burden and a higher risk of progressing to chronic migraine (CM) with associated acut
Autor:
Anna Ambrosini, Emad Estemalik, Julio Pascual, Mallikarjuna Rettiganti, Chad Stroud, Kathleen Day, Janet Ford
Publikováno v:
Journal of managed carespecialty pharmacy. 28(6)
Autor:
Mallikarjuna Rettiganti, Martha D. Port, Janet H. Ford, David W. Ayer, Tobias Kurth, Linda Wietecha, Amaal J. Starling, Dustin D. Ruff
Publikováno v:
Headache
Objective This post hoc study investigated the relationship between patient response in terms of migraine headache day reduction and patient‐reported outcomes of health‐related quality of life (HRQoL) and disability categories. Background Migrain